Gold prices steady ahead of Fed decision; weekly weakness noted
On Tuesday, BTIG analysts maintained their Neutral rating on Vicarious Surgical Inc. (NYSE:RBOT) after the company reported its fourth-quarter financial results for 2024. Vicarious Surgical, a robotics company, disclosed zero revenue and an adjusted loss per share (LPS) of $(2.43). These figures compare favorably to BTIG and consensus estimates, which anticipated an adjusted LPS of $(2.97) and $(2.69), respectively. According to InvestingPro data, the company’s market capitalization stands at $56.9 million, with analysts setting price targets between $8.50 and $13.00.
The company’s operating expenses for the quarter totaled $15.0 million. As of the end of the fiscal year 2024, Vicarious Surgical had approximately $49.1 million in cash, which matched the company’s cash burn for the year. Looking ahead to the fiscal year 2025, Vicarious Surgical expects to burn through roughly $50 million in cash, mirroring the previous year’s levels, assuming operating expenses remain consistent. InvestingPro analysis highlights that while the company holds more cash than debt on its balance sheet, it’s quickly burning through its reserves. Get access to 8 more exclusive ProTips and comprehensive financial analysis with InvestingPro.
Vicarious Surgical also announced that it has encountered delays in its development milestones and timelines, attributing the postponement to supplier dynamics that have restricted access to essential components for the Vicarious System. These supply chain issues have consequently pushed back the initiation of clinical trials and the subsequent submission for De Novo regulatory clearance.
Given the current financial trajectory, Vicarious Surgical anticipates the need to either reduce its cash burn or secure alternative, non-dilutive financing to sustain operations. The company’s management highlighted the challenge of these options in the present economic climate.
In other recent news, Vicarious Surgical Inc. reported its financial results for the fourth quarter of 2024, showcasing significant operational advancements and a reduction in costs. The company achieved a 17% decrease in total operating expenses year-over-year, with research and development expenses dropping by 15.5% and general and administrative expenses decreasing by 18.6%. Despite these reductions, Vicarious Surgical faced a net loss of $63.3 million for the year. The company successfully integrated its Version 1.0 surgical robotic system, which features advanced capabilities, and expanded its manufacturing capabilities while strengthening supply chain redundancies. Vicarious Surgical anticipates a cash burn of approximately $50 million in 2025 and plans to treat its first clinical patients by late 2025. The company also aims to submit its technical dossier by mid-2025, with a de novo submission projected for late 2026. These recent developments indicate Vicarious Surgical’s strategic focus on innovation and operational efficiency as it targets the ventral hernia repair market and explores expansion into other soft tissue procedures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.